Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report

Peer Review reports

Original Submission
14 Jan 2021	Submitted	Original manuscript
20 Feb 2021	Reviewed	Reviewer Report
7 Mar 2021	Reviewed	Reviewer Report
11 Mar 2021	Author responded	Author comments - Kai Conrad Cecil Johnson
Resubmission - Version 2
11 Mar 2021	Submitted	Manuscript version 2
18 Mar 2021	Reviewed	Reviewer Report
19 Mar 2021	Reviewed	Reviewer Report
23 Mar 2021	Author responded	Author comments - Kai Conrad Cecil Johnson
Resubmission - Version 3
23 Mar 2021	Submitted	Manuscript version 3
Publishing
26 Mar 2021	Editorially accepted
1 Apr 2021	Article published	10.1186/s12894-021-00825-4

Back to article page